{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:25:00Z","timestamp":1784676300110,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T00:00:00Z","timestamp":1619913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T00:00:00Z","timestamp":1619913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>No previous study directly compares the fixed day-5 initiation versus the flexible initiation of GnRH antagonist administration in IVF\/ICSI for those patients who are predicted as high ovarian responders without PCOS. To evaluate whether the number of oocytes retrieved is different by using the two GnRH antagonist protocols in Chinese women with predicted high ovarian response except PCOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A randomized controlled trial of 201 infertile women with predicted high ovarian response except PCOS undergoing in vitro fertilization. Ovary stimulation was performed using recombinant FSH and GnRH antagonists. GnRH antagonist ganirelix (0.25\u2009mg\/d) was started either on day 5 of stimulation (fixed group) or when LH was &gt;\u200910\u2009IU\/L, and\/or a follicle with mean diameter\u2009&gt;\u200912\u2009mm was present, and\/or serum E\n                      <jats:sub>2<\/jats:sub>\n                      was &gt;\u2009600\u2009pg\/ml. Patient monitoring was initiated on day 3 of stimulation in flexible group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result(s)<\/jats:title>\n                    <jats:p>\n                      No significant difference was observed between the fixed and flexible groups regarding the number of oocytes retrieved (16.72\u2009\u00b1\u20097.25 vs. 17.47\u2009\u00b1\u20095.88,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u20090.421), the Gonadotropin treatment duration (9.53\u2009\u00b1\u20091.07 vs. 9.67\u2009\u00b1\u20091.03,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u20090.346) and total Gonadotropin dose (1427.75\u2009\u00b1\u2009210.6 vs. 1455.94\u2009\u00b1\u2009243.44,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u20090.381). GnRH antagonist treatment duration in fixed protocol was statistically longer than the flexible protocol (6.57\u2009\u00b1\u20091.17 vs 6.04\u2009\u00b1\u20091.03,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u20090.001). There was no premature LH surge in either protocol.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion(s)<\/jats:title>\n                    <jats:p>Fixed GnRH antagonist administration on day 5 of stimulation appear to achieve a comparable oocyte retrieved compared with flexible antagonist administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/register.clinicaltrials.gov\/\">NCT02635607<\/jats:ext-link>\n                      posted on December 16, 2015 in clinicaltrials.gov.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12884-021-03833-2","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T09:03:49Z","timestamp":1620032629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Fixed versus flexible antagonist protocol in women with predicted high ovarian response except PCOS: a randomized controlled trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Xiu","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,2]]},"reference":[{"key":"3833_CR1","doi-asserted-by":"publisher","first-page":"CD001750","DOI":"10.1002\/14651858.CD001750.pub4","volume":"4","author":"HG Al-Inany","year":"2016","unstructured":"Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4:CD001750. https:\/\/doi.org\/10.1002\/14651858.CD001750.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"3833_CR2","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/humupd\/dmx017","volume":"23","author":"CB Lambalk","year":"2017","unstructured":"Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017;23(5):560\u201379. https:\/\/doi.org\/10.1093\/humupd\/dmx017.","journal-title":"Hum Reprod Update"},{"issue":"5","key":"3833_CR3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/s1472-6483(10)61661-6","volume":"10","author":"H Al-Inany","year":"2005","unstructured":"Al-Inany H, Aboulghar MA, Mansour RT, Serour GI. Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol. Reprod BioMed Online. 2005;10(5):567\u201370. https:\/\/doi.org\/10.1016\/s1472-6483(10)61661-6.","journal-title":"Reprod BioMed Online"},{"issue":"3","key":"3833_CR4","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.fertnstert.2003.07.027","volume":"81","author":"E Escudero","year":"2004","unstructured":"Escudero E, Bosch E, Crespo J, Sim\u00f3n C, Remoh\u00ed J, Pellicer A. Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization\u2013embryo transfer patients. Fertil Steril. 2004;81(3):562\u20136. https:\/\/doi.org\/10.1016\/j.fertnstert.2003.07.027.","journal-title":"Fertil Steril"},{"issue":"4","key":"3833_CR5","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/s0015-0282(02)04920-8","volume":"79","author":"EM Kolibianakis","year":"2003","unstructured":"Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC, et al. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril. 2003;79(4):873\u201380. https:\/\/doi.org\/10.1016\/s0015-0282(02)04920-8.","journal-title":"Fertil Steril"},{"issue":"11","key":"3833_CR6","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1093\/humrep\/17.11.2842","volume":"17","author":"M Ludwig","year":"2002","unstructured":"Ludwig M, Katalinic A, Banz C, Schr\u00f6der AK, L\u00f6ning M, Weiss JM, et al. Tailoring the GnRH antagonist cetrorelix acetate to individual patients\u2019 needs in ovarian stimulation for IVF: results of a prospective, randomized study. Hum Reprod. 2002;17(11):2842\u20135. https:\/\/doi.org\/10.1093\/humrep\/17.11.2842.","journal-title":"Hum Reprod"},{"issue":"8","key":"3833_CR7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/humrep\/deh334","volume":"19","author":"MH Mochtar","year":"2004","unstructured":"Mochtar MH, Dutch Ganirelix Study Group. The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF\/ICSI. Hum Reprod. 2004;19(8):1713\u20138. https:\/\/doi.org\/10.1093\/humrep\/deh334.","journal-title":"Hum Reprod"},{"issue":"3","key":"3833_CR8","first-page":"141","volume":"9","author":"B Hossein Rashidi","year":"2015","unstructured":"Hossein Rashidi B, Behrouzi Lak T, Shahrokh Tehrani E, Davari Tanha F. Fixed versus flexible gonadotropin releasing hormone antagonist protocol in controlled ovarian stimulation for in vitro fertilization in women with polycystic ovary syndrome. J Family Reprod Health. 2015;9(3):141\u20136.","journal-title":"J Family Reprod Health"},{"issue":"2","key":"3833_CR9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.fertnstert.2013.04.029","volume":"100","author":"NP Polyzos","year":"2013","unstructured":"Polyzos NP, Tournaye H, Guzman L, Camus M, Nelson SM. Predictors of ovarian response in women treated with corifollitropin alfa for in vitro fertilization\/intracytoplasmic sperm injection. Fertil Steril. 2013;100(2):430\u20137. https:\/\/doi.org\/10.1016\/j.fertnstert.2013.04.029.","journal-title":"Fertil Steril"},{"issue":"3","key":"3833_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/humrep\/dep436","volume":"25","author":"TG Lainas","year":"2010","unstructured":"Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Alexopoulou E, et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Hum Reprod. 2010;25(3):683\u20139. https:\/\/doi.org\/10.1093\/humrep\/dep436.","journal-title":"Hum Reprod"},{"issue":"4","key":"3833_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/humupd\/dml001","volume":"12","author":"BC Tarlatzis","year":"2006","unstructured":"Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update. 2006;12(4):333\u201340. https:\/\/doi.org\/10.1093\/humupd\/dml001.","journal-title":"Hum Reprod Update"},{"issue":"5","key":"3833_CR12","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.fertnstert.2011.08.015","volume":"96","author":"L Pellatt","year":"2011","unstructured":"Pellatt L, Rice S, Dilaver N, Heshri A, Galea R, Brincat M, et al. Anti-M\u00fcllerian hormone reduces follicle sensitivity to follicle-stimulating hormone in human granulosa cells. Fertil Steril. 2011;96(5):1246\u201351. https:\/\/doi.org\/10.1016\/j.fertnstert.2011.08.015.","journal-title":"Fertil Steril"},{"key":"3833_CR13","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3760\/cma.j.issn.0529\u2014567x.2015.11.002.","volume":"50","author":"Chinese Society for Reproductive Medicine","year":"2015","unstructured":"Chinese Society for Reproductive Medicine. Expert consensus on clinical practice of GnRH antagonist protocol in ART. Chinese J Obstetr Gynecol. 2015;50:805\u20139. https:\/\/doi.org\/10.3760\/cma.j.issn.0529\u2014567x.2015.11.002.","journal-title":"Chinese J Obstetr Gynecol"},{"key":"3833_CR14","unstructured":"Allahbadia G. Manual of ovulation induction: Anshan; 2005."},{"issue":"2","key":"3833_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.fertnstert.2010.05.052","volume":"95","author":"EM Kolibianakis","year":"2011","unstructured":"Kolibianakis EM, Venetis CA, Kalogeropoulou L, Papanikolaou E, Tarlatzis BC. Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial. Fertil Steril. 2011;95(2):558\u201362. https:\/\/doi.org\/10.1016\/j.fertnstert.2010.05.052.","journal-title":"Fertil Steril"},{"key":"3833_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1210\/edrv.18.1.0290","volume":"18","author":"BC Fauser","year":"1997","unstructured":"Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev. 1997;18:71\u2013106. https:\/\/doi.org\/10.1210\/edrv.18.1.0290.","journal-title":"Endocr Rev"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-021-03833-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-021-03833-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-021-03833-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T18:06:12Z","timestamp":1626804372000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-021-03833-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,2]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3833"],"URL":"https:\/\/doi.org\/10.1186\/s12884-021-03833-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-72237\/v1","asserted-by":"object"}]},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,2]]},"assertion":[{"value":"15 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental protocol was established according to the ethical guidelines of the Helsinki Declaration and was approved by the Ethics Committee Review Board of Chongqing Health Center for Women and Children. Written informed consent was obtained from individual participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors declare that we have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"348"}}